Production of Adrenomedullin in Macrophage Cell Line and Peritoneal Macrophage*

Atsushi KuboDagger §, Naoto MinaminoDagger , Yoshitaka IsumiDagger , Takeshi KatafuchiDagger , Kenji KangawaDagger , Kazuhiro Dohi§, and Hisayuki MatsuoDagger

From the Dagger  National Cardiovascular Center Research Institute, Fujishirodai, Suita, Osaka 565-8565 and the § First Department of Internal Medicine, Nara Medical University, Shijo, Kashihara, Nara 634-0813, Japan

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

We demonstrate that adrenomedullin (AM) is produced and secreted from cultured murine monocyte/macrophage cell line (RAW 264.7) as well as mouse peritoneal macrophage. Immunoreactive (IR) AM secreted from RAW 264.7 cells was chromatographically identified to be native AM. To elucidate the regulation mechanism of AM production in macrophage, we examined the effects of various substances inducing differentiation or activation of monocyte/macrophage. Phorbol ester (TPA), retinoic acid (RA), lipopolysaccharide (LPS), and interferon-gamma (IFN-gamma ) increased AM production 1.5-7-fold in RAW 264.7 cells in a dose- as well as time-dependent manner. By LPS stimulation, the AM mRNA level in RAW 264.7 cells was augmented up to 7-fold after 14 h incubation. RA exerted a synergistic effect when administered with TPA, LPS, or IFN-gamma , whereas IFN-gamma completely suppressed AM production in RAW 264.7 cells stimulated with LPS. Dexamethasone, hydrocortisone, estradiol, and transforming growth factor-beta dose-dependently suppressed AM production in RAW 264.7 cells. AM production was also investigated in mouse peritoneal macrophage. Primary mouse macrophage secreted IR-AM at a rate similar to that of RAW 264.7 cells, and its production was enhanced 9-fold by LPS stimulation. AM was found to increase basal secretion of tumor necrosis factor alpha  (TNF-alpha ) from RAW 264.7 cells, whereas AM suppressed the secretion of TNF-alpha and interleukin-6 from that stimulated with LPS. Thus, macrophage should be recognized as one of the major sources of AM circulating in the blood. Especially in cases of sepsis and inflammation, AM production in macrophage is augmented, and the secreted AM is deduced to function as a modulator of cytokine production.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Adrenomedullin (AM)1 is a potent vasorelaxant peptide originally isolated from extracts of human pheochromocytoma by monitoring the elevating activity of platelet cAMP (1). AM shows slight homology with calcitonin gene-related peptide (CGRP) and has a potent and long-lasting depressor effect when injected intravenously into anesthetized rats (1, 2). We have shown that cultured endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) produce and secrete AM into culture medium (3, 4). The production and secretion of AM in VSMC and EC were augmented by interleukin-1 (IL-1), tumor necrosis factor alpha  (TNF-alpha ), and lipopolysaccharide (LPS) (5, 6), which are known to be major factors inducing septic shock (7-9). In the in vivo study, intravenous administration of LPS into rats actually elevated plasma AM concentration 20-fold and augmented AM gene expression in blood vessels, lung, and intestine (10). Plasma AM levels were also remarkably increased in patients with septic shock compared with those in healthy volunteers (11, 12). These data suggest the possibility that AM contributes to induction of refractory hypotension in septic shock.

On the other hand, macrophages are activated by exposure to stimuli of foreign bodies such as LPS and then start to produce and secrete various cytokines, such as IL-1 and TNF-alpha . These data suggest that macrophage is presumed to be another candidate for AM-producing cells in sepsis in addition to VSMC and EC. In fact, Miller et al. (13) have shown the expression of the AM gene in various tumor cell lines, including histiocytic lymphoma cell line (U937), by using the reverse transcriptase-PCR method. Recent reports have also demonstrated that AM or its mRNA is significantly detected in the alveolar macrophages and endometrial macrophages (14, 15). However, the secretion of AM from macrophage has not yet been studied. In this study, we demonstrate that AM is produced and secreted from cultured murine macrophage cell line (RAW 264.7) as well as murine peritoneal macrophage.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Materials-- Human AM-(40-52) and its N-Tyr derivative were synthesized by peptide synthesizer 431A (Applied Biosystems, Foster City, CA). The following materials were used: rat interferon-gamma (IFN-gamma ) (Life Technologies, Inc.), murine recombinant IL-1beta (Intergen, Purchase, NY), mouse recombinant TNF-alpha (Boehringer Mannheim, Mannheim, Germany), dexamethasone, human recombinant transforming growth factor-beta 1 (TGF-beta ), 12-O-tetradecanoyl phorbol-13-acetate (TPA), forskolin, hydrocortisone (Wako Pure Chemical, Osaka, Japan), 17-estradiol, hypoxanthine (Nacalai Tesque, Kyoto, Japan), Escherichia coli LPS (serotype O26: B6) (Parsel+Lorei, Frankfurt, Germany), all-trans-retinoic acid (RA), 8-bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP), low density lipoprotein (LDL) (Sigma), acetylated LDL (ac-LDL) (Biomedical Technologies Inc., Stoughton, MA), and recombinant human macrophage colony-stimulating factor (R & D Systems, Minneapolis, MN). TPA and dexamethasone were first dissolved in ethanol and then diluted with an incubation medium (Dulbecco's modified Eagle's medium (DMEM) (Nikken BioMedical Laboratory, Kyoto, Japan) containing 0.1% bovine serum albumin (BSA)). RA was dissolved in dimethyl sulfoxide and diluted with the incubation medium. LPS was dissolved in 0.9% NaCl solution and diluted with the incubation medium. The other lyophilized substances were dissolved according to the producer's manuals and diluted with the incubation medium. Oxidized LDL (ox-LDL) prepared by the EC method was kindly donated by Dr. Shimokado of this institute. Peptides of rat AM, rat CGRP, rat vasoactive intestinal polypeptide, human AM-(22-52) and human CGRP-(8-37) were obtained from Peptide Institute (Osaka, Japan).

Cell Culture-- RAW 264.7 macrophages (an Abelson leukemia virus-transformed macrophage cell line of Balb/c mouse origin) (16) were obtained from American Type Culture Collection (Rockville, MD) and were cultured in DMEM containing 10% fetal calf serum (FCS) at 37 °C in a humidified atmosphere containing 5% CO2.

Preparation of Conditioned Medium-- RAW 264.7 cells, grown to confluence in a 6-well plate, were washed twice with DMEM, replaced with 1 ml of DMEM containing 0.1% BSA and stimulants, and incubated for 4-14 h at 37 °C (n = 6). To evaluate effects of co-administration of more than two substances, all substances were generally administered at the same time, except that suppressors were added 1 h before administration of stimulants. Viability of RAW 264.7 cells after 14 h incubation was more than 97% by estimating with trypan blue staining. Culture medium (1 ml) was acidified with acetic acid (final concentration, 0.5 M), Triton X-100 added (final concentration, 0.002%), heated at 100 °C for 10 min to inactivate protease, and lyophilized. The lyophilizates were dissolved in radioimmunoassay (RIA) buffer and submitted to RIA for AM.

RIA for AM-- Details of preparation and characterization of antiserum 172CI-7 against human AM-(40-52), which recognizes the C-terminal amide structure common to human, rat, and mouse AM, have been reported by Sakata et al. (17). Monoiodinated N-Tyr-AM-(40-52) isolated by reverse phase HPLC was used as a tracer (3).

Characterization of IR-AM in Culture Medium of RAW 264.7 Cells-- Culture medium (100 ml) of RAW 264.7 cells was acidified with acetic acid (final concentration, 1 M) and boiled for 10 min. After cooling, the acidified medium was loaded onto Sep-Pak C18 ENV cartridges (Waters Chromatography Division, Millipore Corp., Millford, MA) and washed with 0.1% trifluoroacetic acid, and absorbed materials were eluted with 60% CH3CN containing 0.1% trifluoroacetic acid. The eluate was evaporated and subjected to gel filtration on Sephadex G-50 column (fine, 1.5 × 100 cm, Amersham Pharmacia Biotech, Sweden). Fractions containing IR-AM were pooled and separated by reverse phase HPLC on a µ-Bondasphere 5 µ C18 column (300 Å, 3.9 × 150 mm, Millipore Corp.) using a linear gradient elution of CH3CN from 10 to 60% in 0.1% trifluoroacetic acid over 60 min.

RNA Blot Analysis-- RAW 264.7 cells, grown to confluence in a 10-cm dish, were washed twice with DMEM and incubated with stimulants in the incubation medium for 4-14 h. Total RNA (10 µg), extracted by the acid guanidinium thiocyanate/phenol/chloroform method, was denatured, electrophoresed, and then transferred to Zeta probe membrane (Bio-Rad) (3). Hybridization and washing of the membrane were carried out as reported (3). EcoRI-BglI cDNA fragment of rat AM (nucleotide 153-422), EcoRI-BamHI cDNA fragment of rat glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (nucleotide 492-799), cDNA fragments of mouse TNF-alpha (nucleotide 169-651) and mouse IL-6 (nucleotide 123-431) were used as probes (8, 18, 19). Band intensity was estimated by BioImage analyzer (BAS 5000, Fuji Photofilm, Tokyo, Japan). AM, TNF-alpha , and IL-6 mRNA band intensities were compared after correcting band intensity using GAPDH mRNA band as an internal standard.

Determination of TNF-alpha , IL-6, and IL-1beta Concentrations-- TNF-alpha , IL-6, and IL-1beta concentrations were measured with a solid-phase sandwich enzyme-linked immunoadsorbent assay (ELISA) specific for murine TNF-alpha , IL-6, and IL-1beta (Genzyme, Cambridge, MA) after 4 h incubation of the cells in the presence or absence of AM (10-6 M), because the previous study reported that the TNF-alpha bioactivity in RAW 264.7 cells increased rapidly and plateaued after 4 h of LPS stimulation (20).

Quantification of AM, TNF-alpha , and IL-6 mRNA by Real Time Quantitative PCR-- RAW 264.7 cells, grown to confluence in a 6-well dish, were washed twice with DMEM and incubated with stimulants in the incubation medium for 0-8 h. Total RNA (2 µg), extracted by the RNA zol B (Tel-Test Inc., Friendwood, TX), was reverse-transcribed into cDNA with SuperScript reverse transcriptase (Life Technologies, Inc.). Mouse AM cDNA, TNF-alpha cDNA, IL-6 cDNA, and GAPDH cDNA were each amplified with respective pairs of the following oligonucleotides: TCCTGGACGAGCAGAACACAAC (base 1704-1725, sense primer) and TGGTTCATGCTCTGGCGGTA (base 1797-1816, antisense primer) for AM cDNA (21); GTGATCGGTCCCCAAAGG (base 326-343) and GGGTCTGGGCCATAGAACTG (base 394-414) for TNF-alpha cDNA (18); TGAAGTTCCTCTCTGCAAGAGACT (base 33-56) and TAGGGAAGGCCGTGGTTGT (110-128) for IL-6 cDNA (19); ACATGTTCCAGTATGACTCCACTCAC (base 174-199) and TCTCGCTCCTGGAAGATGGT (base 282-301) for GAPDH cDNA (22). To measure mouse AM, TNF-alpha , IL-6, and GAPDH mRNA levels, a novel quantitative PCR method, real time quantitative PCR (Prism 7700 Sequence Detector, Applied Biosystems), was performed as reported previously (23, 24). We used the following oligonucleotide probes labeled with 6-carboxyfluorescein as reporter fluorescence and 6-carboxytetramethylrhodamine as quencher fluorescence: ACAAGCCAGCAATCAGAGCGAAGC (bases 1735-1758) for AM (21); ATGAGAAGTTCCCAAATGGCCTCCCT (bases 346-369) for TNF-alpha (18); TTGCCTTCTTGGGACTGATGCTGGT (bases 66-90) for IL-6 (19); and AACGGCACAGTCAAGGCCGAGAAT (bases 209-233) for GAPDH (22). AM, TNF-alpha , and IL-6 mRNA levels were compared after correcting them by GAPDH mRNA level as an internal standard. Known amounts of cDNA fragments of mouse AM (bases 1704-1816), mouse TNF-alpha (bases 326-414), mouse IL-6 (bases 33-128), and mouse GAPDH (bases 174-301) were used as standards. The data were averages of three individual experiments.

Preparation of Mouse Peritoneal Macrophages-- Thioglycolate-elicited macrophages were collected by peritoneal lavage with pyrogen-free saline at 7 days after intraperitoneally injecting 2 ml of sterile thioglycolate to 6-week-old C3H/He mice (Charles River Japan, Yokohama, Japan). Thioglycolate-elicited macrophages were cultured in 10-cm dishes at 5 × 105 cells/dish in RPMI 1640 medium (Life Technologies, Inc.) supplemented with 10% FCS. After 1 h incubation to allow for adherence of macrophages, the dishes were washed to remove nonadherent cells. Macrophage monolayers were then cultured in RPMI 1640 medium containing 10% FCS with TPA, RA, LPS, or IFN-gamma for 24 h (n = 5).

Intracellular cAMP Measurement-- RAW 264.7 cells and mouse peritoneal macrophages, grown to confluence in 24-well plates, were washed thoroughly with DMEM. The media were then replaced with Hepes-buffered DMEM (pH 7.4, 25 mM Hepes, 0.01% BSA, and 0.5 mM isobutylmethylxanthine) containing various concentrations of rat AM, rat CGRP, and their antagonists, and the cells were incubated precisely for 10 min. The reaction was terminated by aspirating the media followed by addition of 0.2 M HCl and 5 mM EDTA. After scraping the cells, the cell suspension was sonicated and centrifuged. From the resulting extracts, the aliquot (100 µl) was lyophilized, and its cAMP content was measured by a specific RIA as reported previously (n = 3) (25).

Statistical Analysis-- Statistical analysis of the results were performed by one-way analysis of variance, followed by a multiple comparison test (Fisher's test). All data were expressed as means ± S.E. A level of p < 0.05 was considered to be statistically significant.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Production and Secretion of IR-AM from RAW 264.7 Cells and Its Chromatographic Identification-- We measured IR-AM content in culture medium of RAW 264.7 cells after incubation for 4, 8, or 14 h by using RIA specific to AM. As shown in Fig. 1, IR-AM was accumulated in the medium almost linearly up to 14 h without any stimulation. Intracellular IR-AM content of RAW 264.7 cells was also measured after extraction and condensation. The intracellular level of IR-AM was constant and much lower (less than 10%) than that in culture medium after 14 h incubation (data not shown). This result suggests that IR-AM synthesized in RAW 264.7 cells is not stored in the cells but is secreted constitutively into the medium after synthesis. Thus, we measured IR-AM content in the culture medium to evaluate IR-AM production in RAW 264.7 cells.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 1.   Time-dependent AM production in RAW 264.7 cells stimulated with TPA, RA, LPS, and IFN-gamma . RAW 264.7 cells were stimulated with TPA, RA, LPS, and IFN-gamma for 4, 8, and 14 h at concentrations listed below. After stimulation, IR-AM concentration in culture medium was measured by RIA specific for AM. Closed circles, TPA (10-7 M); closed triangle, RA (10-5 M); open circles, LPS (100 ng/ml); open triangles, IFN-gamma (100 units/ml); closed squares, control (without stimulation). Each point represents the mean ± S.E. of six separate dishes. *, p < 0.05.

To identify IR-AM secreted into culture medium from RAW 264.7 cells, we characterized IR-AM by gel filtration and reverse phase HPLC. The culture medium was collected after stimulation with 10-7 M TPA for 14 h, since the secretion rate of IR-AM from RAW 264.7 cells was low without any stimulation. In Sephadex G-50 gel filtration, more than 70% of total IR-AM in the culture medium was eluted at a molecular weight region corresponding to 6000 (Fig. 2a). Fractions 33-35 of 6000 IR-AM were pooled, and a portion of the pooled fractions was subjected to reverse phase HPLC. More than 70% of IR-AM was eluted at a retention time almost identical to that of native rat AM (Fig. 2b). Based on these data, we conclude that IR-AM secreted from RAW 264.7 cells is chromatographically composed of a single component that has properties very close to those of rat AM of 50 residues. In fact, the amino acid sequence of mouse AM has recently been determined which has only three homologous replacements in the 50-residue peptide compared with rat AM (20).


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 2.   Characterization of IR-AM secreted from RAW 264.7 cells. a, Sephadex G-50 gel filtration of IR-AM from culture medium of RAW 264.7 cells stimulated with TPA. Sample: 100 ml eq of culture medium. Column: 1.5 × 100 cm. Solvent: 2 M acetic acid. Fraction size: 4.0 ml/tube. Flow rate: 5.0 ml/h. b, reverse phase HPLC of IR-AM from culture medium of RAW 264.7 cells stimulated with TPA. Sample: 2/3 of fractions 33-35 (a). Column: µ-Bondasphere 5 µ C18 column (300 Å, 3.9 × 150 mm). Flow rate: 1.0 ml/min. Fraction size: 0.5 ml/tube. Solvent system: Linear gradient elution from 10 to 60% CH3CN in 0.1% trifluoroacetic acid over 60 min. Arrows indicate elution positions of BSA (1), human AM-(1-52) (2), human AM-(22-52) (3), human AM-(40-52) (4), NaCl (5), and rat AM-(1-50) (6).

Regulation of IR-AM Production in RAW 264.7 Cells-- We first examined various substances that induced monocyte-macrophage differentiation or activation (26). Among them, TPA, RA, LPS, and IFN-gamma significantly increased IR-AM secretion from RAW 264.7 cells compared with the control (Table I). In contrast, TNF-alpha and IL-1beta , which augmented AM production in rat VSMCs and ECs (5, 6), showed no apparent effect on AM production in RAW 264.7 cells.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Effect of various substances on AM production in RAW 264.7 cells
RAW 264.7 cells were incubated with various substances, which induced monocyte-macrophage differentiation or activation, as well as steroids, and lipoproteins in the indicated concentrations for 14 h. IR-AM concentrations secreted into culture media were measured by RIA specific for AM. Each value represents mean ± S.E. of six separate dishes. M-CSF, macrophage-colony stimulating factor; VIP, vasoactive intestinal polypeptide.

TPA, RA, LPS, and IFN-gamma dose-dependently stimulated secretion of IR-AM from RAW 264.7 cells, and increased IR-AM concentration in the media to 164, 190, 600, and 460% of the control at concentrations of 10-7 and 10-5 M, 1000 ng/ml, and 100 units/ml, respectively (Fig. 3). Time-dependent effects of these substances in concentrations inducing almost maximal stimulation are shown in Fig. 1. AM production was augmented after 8 h stimulation in the cases of TPA, RA, and IFN-gamma , whereas LPS was found to have already enhanced AM production before 4 h stimulation.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 3.   Dose-dependent AM production in RAW 264.7 cells by stimulation with TPA, RA, LPS, and IFN-gamma . RAW 264.7 cells were stimulated with TPA (a), RA (b), LPS (c), and IFN-gamma (d) of indicated concentrations for 14 h. IR-AM concentration in culture medium was measured by RIA specific for AM. Each value represents the mean ± S.E. of six separate dishes. *, p < 0.05.

AM gene transcription was estimated by RNA blot analysis, and AM mRNA levels in RAW 264.7 cells stimulated with LPS (100 ng/ml) were measured after 0, 4, 8, and 14 h stimulation. LPS time-dependently increased AM mRNA level (Fig. 4, a and c), and this result was parallel to the peptide production level of AM in RAW 264.7 cells. Furthermore, AM mRNA level after 8 h stimulation was elevated according to the increase of LPS concentration and was also well correlated with the peptide production level of AM shown in Fig. 3c (Fig. 4, b and d). AM mRNA levels were also increased by stimulation with RA, TPA, and IFN-gamma to 116, 148, and 199% of the control in concentrations of 10-7 and 10-5 M and 100 units/ml after 8 h stimulation, respectively (data not shown).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 4.   RNA blot analysis of AM gene transcripts in RAW 264.7 cells. Total cellular RNA was extracted from RAW 264.7 cells after stimulation with LPS and was subjected to RNA blot analysis for AM mRNA. a, AM mRNA levels in RAW 264.7 cells after 0, 4, 8, and 14 h stimulation with LPS (100 ng/ml). b, AM mRNA levels in RAW 264.7 cells after 8 h stimulation with 0, 1, 10, and 100 ng/ml LPS. c, RNA blot analysis of AM transcripts in RAW 264.7 cells after 0, 4, 8, and 14 h stimulation with LPS (100 ng/ml). d, RNA blot analysis of AM transcripts in RAW 264.7 cells after 8 h stimulation with 0, 1, 10, and 100 ng/ml LPS. Lower panels of c and d indicate RNA blot analysis of GAPDH transcripts. AM mRNA level was estimated after correcting band intensity using GAPDH mRNA level as an internal standard.

Next, we examined effects of steroid hormones on IR-AM production in RAW 264.7 cells. Dexamethasone, hydrocortisone, and estradiol reduced IR-AM concentrations to 24, 49, and 67% of the control at the concentrations of 10-5, 10-6, and 10-5 M, respectively (Fig. 5, a, b, and c). We also investigated the effects of TGF-beta that has been recognized as a potential inhibitor of macrophage activation (27). TGF-beta suppressed AM production to 75% of the control in a concentration of 10 ng/ml (Fig. 5d).


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 5.   Dose-dependent inhibition of AM production with dexamethasone, hydrocortisone, estradiol, and TGF-beta in RAW 264.7 cells. RAW 264.7 cells were incubated for 14 h in the presence of dexamethasone (Dexa) (a), hydrocortisone (Hyd) (b), estradiol (c), and TGF-beta (d) at the indicated concentrations. IR-AM concentration in culture medium was measured by RIA specific for AM. Each value represents the mean ± S.E. of six separate dishes. *, p < 0.05.

To evaluate cooperative effects of stimulators and suppressors, IR-AM concentration in the cultured medium of RAW 264.7 cells was measured by co-administering substances that had significantly altered AM production. When 10-5 M of RA was administered with TPA (10-8 M), LPS (100 ng/ml), or IFN-gamma (100 units/ml), IR-AM concentration in the medium was elevated to a level higher than that deduced from summation of the effect of each substance (Fig. 6). Specifically, simultaneous addition of LPS and RA increased IR-AM content in the medium to 10 times higher than that of control. Although IL-1beta , TNF-alpha , and LPS showed additive effects on AM production in cultured rat VSMCs (5), combining these three substances did not induce any cooperative effect on AM production in RAW 264.7 cells (data not shown). Since combination of LPS and IFN-gamma has been reported to induce synergistic effects on cytotoxic activity and nitric oxide (NO) production in RAW 264.7 cells (28), we examined the effect of co-administration of LPS and IFN-gamma . In contrast, IFN-gamma suppressed IR-AM secretion stimulated with 10 ng/ml LPS even at a concentration of 1 unit/ml (Fig. 7).


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of co-administration of RA with TPA, LPS, or IFN-gamma on AM production in RAW 264.7 cells. 10-5 M RA was administrated with TPA (10-8 M), LPS (100 ng/ml), or IFN-gamma (100 units/ml) to RAW 264.7 cells and the cells were incubated for 14 h. Closed bars and open bars indicate IR-AM concentrations in the presence or absence of RA, respectively. Each value represents the mean ± S.E. of six separate dishes. Significant difference (p < 0.05) was observed in all cases between the presence and absence of RA.


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 7.   Inhibitory effect of IFN-gamma on AM production in RAW 264.7 cells stimulated with LPS. LPS and IFN-gamma were simultaneously administered to RAW 264.7 cells as indicated at the bottom of the figure. IR-AM content in the culture medium was measured after 14 h incubation by RIA specific for AM. Each value represents the mean ± S.E. of six separate dishes. *, p < 0.05.

We also examined effects of glucocorticoids and TGF-beta on AM production in RAW 264.7 cells stimulated with LPS, since these substances have been reported to suppress production of NO and cytokines, such as TNF-alpha , under stimulation with LPS (29, 30). When dexamethasone and hydrocortisone were each administered simultaneously with LPS, these substances elicited slight inhibitory effects on AM secretion from RAW 264.7 cells (data not shown). However, 1 h pretreatment of the cells with dexamethasone or hydrocortisone strongly inhibited IR-AM production stimulated with LPS (100 ng/ml) (Fig. 8). These results indicate that glucocorticoids are potent inhibitors of AM production in RAW 264.7 cells, overcoming the effect of LPS. TGF-beta (10 ng/ml) also suppressed AM production to 60% that stimulated with LPS (100 ng/ml) (data not shown).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 8.   Inhibitory effects of dexamethasone and hydrocortisone on AM production in RAW 264.7 cells stimulated with LPS. Dexamethasone (Dexa) (a) and hydrocortisone (Hyd) (b) of indicated concentrations were preincubated for 1 h before LPS stimulation. After preincubation, the medium was replaced, and RAW 264.7 cells were incubated for 14 h with dexamethasone (a) and hydrocortisone (b) in the presence of LPS (100 ng/ml). IR-AM content in the culture medium was measured after 14 h incubation by RIA specific for AM. Each value represents the mean ± S.E. of six separate dishes. *, p < 0.05.

We examined the effect of the substances that elevate intracellular cAMP concentrations, such as forskolin, 8-Br-cAMP, and vasoactive intestinal polypeptide, on AM production in RAW 264.7 cells, since we previously showed that these substances suppressed AM production in VSMCs (31). However, these substances elicited no significant effect on AM production in RAW 264.7 cells (Table I).

Finally, effects of lipoproteins, such as LDL, ac-LDL, and ox-LDL, on AM production in RAW 264.7 cells were estimated, since macrophages were well known to have an important role in cholesterol deposition in atherosclerosis (32). LDL, ac-LDL, and ox-LDL significantly increased AM production in RAW 264.7 cells to 141, 123, and 181% of the control, respectively (Table I).

AM Modulates Secretion and Gene Transcription of TNF-alpha and IL-6 in RAW 264.7 Cells-- To elucidate physiological functions of AM secreted from macrophages and their cell lines, we examined the effects of AM on production of inflammatory cytokine, TNF-alpha , IL-1beta , and IL-6, in RAW 264.7 cells, since these cytokines were known to play important roles in the pathophysiology of sepsis. AM increased TNF-alpha concentration in the culture medium of RAW 264.7 cells to about 160% in the absence of LPS stimulation (Fig. 9a). LPS (1 ng/ml) markedly enhanced TNF-alpha production about 120-fold in RAW 264.7 cells. On the contrary, AM significantly suppressed TNF-alpha secretion from RAW 264.7 cells stimulated with LPS maximally to about 50%, and the inhibitory effect was observed even in high concentrations of LPS (Fig. 9b). RNA blot analysis demonstrated that LPS dose-dependently increased TNF-alpha mRNA level in RAW 264.7 cells after 4 h stimulation. AM also suppressed TNF-alpha mRNA level in RAW 264.7 cells stimulated with 1, 10, 100, and 1000 ng/ml LPS to 69, 80, 62, and 70%, respectively (Fig. 10a).


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 9.   Effects of AM on TNF-alpha secretion from RAW 264.7 cells. a, TNF-alpha concentration in the culture medium was measured by ELISA after 4 h incubation of RAW 264.7 cells with AM (10-6 M). b, TNF-alpha concentration was measured by ELISA after 4 h incubation of RAW 264.7 cells with 1, 10, 100 and 1000 ng/ml LPS in the presence (open bar) or absence (closed bar) of AM (10-6 M). Each value represents the mean ± S.E. of four separate dishes. *, p < 0.05.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 10.   Quantification of TNF-alpha mRNA level in RAW 264.7 cells. a, TNF-alpha mRNA levels in RAW 264.7 cells were evaluated by RNA blot analysis after 4 h stimulation of with 1, 10, 100, 1000 ng/ml LPS in presence (open bar) or absence (closed bar) of AM (10-6 M). b, TNF-alpha mRNA levels in RAW 264.7 cells after 0, 1, 2, 4, and 8 h stimulation with LPS (100 ng/ml) were measured by real time quantitative PCR in the presence (open bars) or absence (closed bars) of AM (10-6 M) (n = 3). c, TNF-alpha mRNA levels in RAW 264.7 cells after 4 h stimulation with 0, 1, 10, and 100 ng/ml LPS were measured by real time quantitative PCR in the presence (open bars) or absence (closed bars) of AM (10-6 M) (n = 3). TNF-alpha mRNA level was estimated after correcting it using GAPDH mRNA level as an internal standard.

Basal secretion levels of IL-1beta and IL-6 were below detection limits (10 and 5 pg/ml, respectively). However, LPS enhanced IL-6 production (27.6 ± 0.57 pg/ml) at a concentration of 100 ng/ml, and AM slightly but significantly reduced IL-6 concentration (22.8 ± 1.78 pg/ml, p < 0.05) in a manner similar to that of TNF-alpha . RNA blot analysis also demonstrated that AM suppressed IL-6 mRNA levels to about 85% in the presence of 100 ng/ml LPS (data not shown). On the other hand, IL-1beta production in RAW 264.7 cells was not significantly altered by the addition of AM.

Measurement of Mouse AM mRNA and TNF-alpha mRNA Levels By Using Real Time Quantitative PCR-- To evaluate whether real time quantitative PCR is usable for quantifying the amount of mRNA, we first measured mouse AM levels in RAW 264.7 cells stimulated with LPS. As shown in Fig. 11a, the fluorescent emission data were collected during the PCR amplification, and threshold cycles were calculated by determining the point at which the fluorescence intensity exceeded the level 10 times higher than the standard deviation of the base lines. As the larger amounts of the standard were applied, the significant emission of fluorescence was detected at the earlier phase of threshold cycle in the amplification plot. The threshold cycle decreased linearly with increasing quantity of mouse AM cDNA standard (r = 0.998, p < 0.0001), indicating that the amount of mRNA was correctly evaluated in a wide range by this method (Fig. 11b). By using the real time quantitative PCR, we demonstrated that LPS time- and dose-dependently increased AM mRNA levels in RAW 264.7 cells in profiles similar to those measured by RNA blot analysis (Fig. 11, c and d). Thus, the real time quantitative PCR was shown to be usable for determining the amounts of mRNA instead of RNA blot analysis.


View larger version (47K):
[in this window]
[in a new window]
 
Fig. 11.   Quantification of AM mRNA level in RAW 264.7 cells by real time quantitative PCR. a, amplification plots of AM mRNA levels measured by real time quantitative PCR. Standard samples of 0.001, 0.01, 0.1, 1, 10, 100, and 1000 fg were amplified, and the Delta Rn (fluorescent emission) was plotted against the cycle number. As the larger amounts of the standard sample were applied, the significant emission of fluorescence was detected at the earlier phase of threshold cycle in the amplification plot. Threshold cycle (Ct) was calculated by determining the point at which the fluorescence exceeded 10 times the standard deviation of the base line. b, standard curve for AM mRNA levels measured by real time quantitative PCR. The amounts of standard samples were plotted versus threshold cycles in duplicates. c, AM mRNA levels were evaluated by real time quantitative PCR after 0, 1, 2, 4, and 8 h stimulation with LPS (100 ng/ml) (n = 3). d, AM mRNA levels were measured by real time quantitative PCR after 4 h stimulation with 0, 1, 10, and 100 ng/ml LPS (n = 3). AM mRNA level was compared after correcting it using GAPDH mRNA level as an internal standard (c and d). *, p < 0.05.

Next, TNF-alpha mRNA level in RAW 264.7 cells was evaluated by real time quantitative PCR. TNF-alpha mRNA level was time-dependently increased up to 8 h by stimulation with LPS (100 ng/ml), and AM (10-6 M) suppressed TNF-alpha mRNA levels maximally to 77% at 4 h after LPS stimulation (Fig. 10b). In addition, LPS dose-dependently increased TNF-alpha mRNA levels, and AM (10-6 M) suppressed TNF-alpha mRNA levels maximally to 66% at a dose of 10 ng/ml after 4 h of stimulation (Fig. 10c).

Production of IR-AM in Murine Peritoneal Macrophages-- Based on data obtained from macrophage cell line, RAW 264.7, we next assessed whether AM was produced and secreted from primary mouse macrophages. Mouse primary macrophages secreted IR-AM without any stimulation at a rate (0.2 ± 0.04 fmol/105 cells/24 h) about 15% that of RAW 264.7 cells (Table II). Peritoneal exudate macrophages were treated with TPA (10-7 M), RA (10-6 M), LPS (100 ng/ml), and IFN-gamma (100 units/ml) for 24 h. Among them, LPS increased IR-AM content in the culture medium about 7-fold compared with that of control, but the others did not alter IR-AM concentrations (Table II). When 1000 ng/ml LPS was added to primary macrophages, IR-AM concentration was increased at least 9-fold over 24 h. To examine synergistic effects, TPA, RA, and IFN-gamma were co-administered with 100 ng/ml LPS and incubated for 24 h (Table II). As in the case of that observed in RAW 264.7 cells, LPS dose-dependently augmented AM production, and co-administration of LPS and RA synergistically enhanced their stimulatory effects on IR-AM secretion from mouse primary macrophage. With regard to the combination of LPS and IFN-gamma , IFN-gamma also inhibited IR-AM secretion stimulated with LPS in a manner similar to that of RAW 264.7 cells. However, TPA inhibited IR-AM secretion stimulated with LPS in contrast to the results obtained in RAW 264.7 cells. Based on these results, mouse primary macrophages were shown to have the ability to produce and secrete AM. Regulation of AM production in primary macrophage was deduced to be similar to that of RAW 264.7 cells, as observed in the case of LPS, but was not completely identical to that of the established cell line.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Production of AM in mouse peritoneal macrophages
Mouse primary macrophages, elicited by the thioglycolate, were stimulated with TPA, RA, LPS, or IFN-gamma of indicated concentrations for 24 h. Furthermore, 100 ng/ml LPS was co-administered to primary macrophage with TPA, RA, and IFN-gamma of indicated concentrations and cultured for 24 h. IR-AM concentrations in cultured medium were measured by RIA specific for AM. Each value represents mean ± S.E. of five separate dishes.

Intracellular cAMP Production in RAW 264.7 Cells and Mouse Peritoneal Macrophages-- Since AM was shown to modulate production of cytokines in RAW 264.7 cells, we examined the expression and properties of AM receptors on this macrophage cell line and mouse peritoneal macrophages. AM (10-6 M) did not increase cAMP production in RAW 264.7 cells (data not shown). On the other hand, AM (10-6 M) augmented the intracellular cAMP level in mouse peritoneal macrophages 6.7-fold compared with the basal level. Rat CGRP dose-dependently elevated the intracellular cAMP level with an ED50 value of 7.6 × 10-10 M, and AM antagonist, human AM-(22-52) did not affect the ED50 value. In the presence of 10-6 M CGRP antagonist, human CGRP-(8-37), the dose-response curve of the cAMP production was markedly shifted to the high concentration side, and the ED50 value was 145 times higher than that without CGRP antagonist. In contrast, the ED50 value of rat AM in the cAMP production assay was 4.3 × 10-7 M, being 570 times higher than that of rat CGRP. Furthermore, the dose-response curve of AM was not shifted with human AM-(22-52) but with human CGRP-(8-37). Based on these results, the receptors expressed on mouse peritoneal macrophages are found to be specific for CGRP, and AM is not deduced to significantly stimulate the cAMP production under the physiological conditions.

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

In this study, we demonstrated that the macrophage cell line RAW 264.7 produced and secreted IR-AM that was identified as native AM by chromatographic procedures (Fig. 2). Although the production level of AM in RAW 264.7 cells was lower than that of cultured rat ECs and VSMCs (4, 5), we found substances that stimulated differentiation and activation of monocyte/macrophage potently augmented AM production (Table I). As shown in Fig. 3, the secretion rate of AM from RAW 264.7 cells stimulated with LPS or IFN-gamma was comparable to that of cultured VSMCs, indicating that monocyte/macrophage system was another candidate for secreting AM into the bloodstream.

TPA and IFN-gamma increased IR-AM concentration in the culture medium of RAW 264.7 cells (Figs. 1 and 3). TPA, a potent activator of protein kinase C, induces the differentiation of this cell line into macrophage and stimulates production of IL-1beta and TNF-alpha (7, 33). IFN-gamma is also known to be a potent inducer of differentiation of monocyte/macrophage and to enhance production of NO, TNF-alpha , and IL-1beta (28, 34, 35). RA increased AM production in RAW 264.7 cells (Figs. 1 and 3) and stimulated AM production synergistically when administered with TPA, IFN-gamma , or LPS (Fig. 6). RA has been reported to activate macrophage and potentiate phagocytosis and IL-1 activity in RAW 264.7 cells (36). This result suggests that RA activates macrophages to conditions where they can respond more potently to any stimulation and produce AM at higher rates. AM production is thought to be increased by stimulators that induce differentiation or activation of macrophages. On the other hand, mouse peritoneal macrophages failed to increase AM production by stimulation with TPA, RA, and IFN-gamma . RAW 264.7 cells were established from peritoneal macrophages, but the cells have been transformed and immortalized by infection of Abelson leukemia virus (16). Although peritoneal macrophages and RAW 264.7 cells share many biological features, these cells are reported to elicit different responses in NO synthesis when stimulated with phorbol ester (37). We also observed in this study that AM increased cAMP production in peritoneal macrophages but not in RAW 264.7 cells. These findings lead us to deduce that the differences in results are due to different properties of established cell lines and primary culture.

Glucocorticoids have been shown to enhance AM production, and estradiol increased it in rat EC and VSMC EC (6, 38), but these reagents were found to be potent suppressors of AM production in RAW 264.7 cells (Fig. 5). Glucocorticoids have been shown to antagonize differentiation of macrophage (39) and are potent anti-inflammatory agents that inhibit production and release of NO and cytokines, such as IL-1, IL-6, and TNF-alpha , from macrophages (29, 40-42). These data indicate that gene transcription and production of AM in the macrophage cell line are regulated in a manner similar to NO synthase and inflammatory cytokines but distinct from AM in EC and VSMC (4-6, 38). In the vascular wall, glucocorticoids are known to increase vascular tone, but AM secreted from EC and VSMC contributes to reduction of vascular tone (43, 44). In the monocyte/macrophage system, AM is shown to be produced and secreted from RAW 264.7 cells and to participate in the regulation of TNF-alpha and IL-6 production. Taken together, we deduce that the intracellular signal integration mechanism regulating transcription of AM gene must be different in each cell line in order to exert its divergent effects after secretion from the cells. TGF-beta is recognized as a potential inhibitor for activation of macrophage as well as for production of NO and TNF-alpha (27, 30) and also suppresses AM production in RAW 264.7 cells. Based on these results, AM production in RAW 264.7 cells is thought to be increased or decreased mainly by the substances that stimulate or suppress differentiation and activation of macrophages.

We have reported that production and secretion of AM from VSMC and EC are augmented by LPS stimulation (5, 6) and that intravenous administration of LPS into rats increases plasma AM concentration 20-fold and augments AM gene transcription in almost all tissues including blood vessels (10). Furthermore, an average concentration of plasma AM in patients with septic shock has recently been reported to be 10-45 times higher than that of healthy volunteers (11, 12). Based on these data, we have attributed high plasma AM concentrations in LPS-injected rats and in patients with septic shock to the elevated production of AM in ECs and VSMCs. As shown in the present study, LPS is shown to be the most potent stimulator of AM production and gene transcription in RAW 264.7 cells (Figs. 1, 3, 4, and 11). Even in primary mouse macrophages, LPS in a concentration of 1000 ng/ml also increases AM production about 9-fold compared with that of control. We also found in our recent studies that human leukemia cell line and peripheral blood monocytes produce AM according to their differentiation into macrophages and that LPS stimulation augments AM production in monocyte-derived macrophages (45). Regulation of AM production in RAW 264.7 cells is found to be similar to that of inflammatory cytokines, such as IL-1, IL-6, and TNF-alpha , which contribute to the pathophysiology of sepsis (7-9). These data indicate that macrophage is another candidate for secreting circulatory AM in the case of sepsis.

As shown in Fig. 8, glucocorticoids strongly suppressed AM production in RAW 264.7 cells even in the presence of LPS. In the in vivo experiments, glucocorticoids have been reported to induce tolerance to LPS and reduce mortality in animals with experimentally induced septic shock (46). Glucocorticoids suppress production of inflammatory cytokines and NO, which results in reduction of vasodilation (40-42). This suppressive effect on production of inflammatory cytokines and NO is thought to be one of the reasons why glucocorticoid induces tolerance to LPS and prevents septic shock. Thus, our results raise the possibility that AM produced in macrophage is an additional modulator in the pathogenesis of sepsis. Pretreatment of macrophages with TGF-beta has been reported to attenuate their ability to produce TNF-alpha , NO, and prostaglandin E2 in response to LPS (30, 47). AM production in RAW 264.7 cells was also suppressed by TGF-beta (Fig. 5d). In this study, macrophage and macrophage cell line were shown to actively produce AM after LPS stimulation, whereas AM production was suppressed by glucocorticoids and TGF-beta . These results suggest that AM plays a significant role in the pathogenesis of sepsis and inflammation in addition to its function as a vasodilator.

Our previous study has shown that IFN-gamma suppresses AM production in rat VSMCs (31). However, IFN-gamma stimulates AM secretion in RAW 264.7 cells when administered alone (Fig. 3). AM gene has many IFN-gamma -responsive elements in the promoter region (48). McDowell et al. (49) reported that RAW 264.7 cells, but not less mature WEHI-3 cells, were able to utilize transfected IFN-gamma -responsive elements and induce rapid transcription by IFN-gamma stimulation. These facts indicate that the IFN-gamma -responsive element is utilized differently depending on the cells and that in RAW 264.7 cells IFN-gamma induces gene transcription of AM via IFN-gamma -responsive elements. On the contrary, IFN-gamma strongly inhibits AM secretion from RAW 264.7 cells and mouse peritoneal macrophages stimulated with LPS (Fig. 7 and Table II). In the case of RAW 264.7 cells stimulated with LPS, IFN-gamma was reported to induce hyporesponsiveness to LPS and reduce the production of TNF-alpha (50). Another report also showed that IFN-gamma strongly suppressed the expression of IL-1 beta gene stimulated with LPS (51). These data suggest that IFN-gamma acts as inhibitory cytokine under the chronically inflammatory conditions stimulated with LPS. Since the effects of IFN-gamma are different in each cell type and dependent on the physiological condition of the cells, discordant responses of IFN-gamma are likely to be derived from differences in transcriptional regulation between VSMCs and RAW 264.7 cells as well as between the presence and absence of LPS.

In order to identify physiological functions of AM secreted from macrophages, we examined whether AM modulates secretion of TNF-alpha , IL-1beta , and IL-6, the cytokines mainly produced in macrophages and RAW 264.7 cells (7-9). As shown in Fig. 9, AM increased a basal secretion level of TNF-alpha from RAW 264.7 cells, whereas AM significantly suppressed TNF-alpha secretion when the cells were stimulated with LPS. AM was also shown to suppress secretion of IL-6 stimulated with LPS in this study. RNA blot analysis and real time quantitative PCR analysis showed that AM lowered TNF-alpha and IL-6 mRNA levels in RAW 264.7 cells stimulated with LPS (Fig. 10), suggesting that AM inhibits cytokine production at the step of gene transcription. Kamoi et al. (52) reported that AM inhibited secretion of cytokine-induced neutrophil chemoattractant, belonging to IL-8 superfamily, in rat alveolar macrophages stimulated with LPS. These results indicate that AM secreted from macrophages not only dilates blood vessels but also modulates production of inflammatory cytokines, TNF-alpha , IL-6, and cytokine-induced neutrophil chemoattractant.

To assess the properties of AM receptors expressed on RAW 264.7 cells and mouse peritoneal macrophages, we measured intracellular cAMP concentrations in these cells. However, AM did not significantly increase the intracellular cAMP concentration in RAW 264.7 cells. In the case of mouse peritoneal macrophages, only 10-6 M AM increased intracellular cAMP concentration, and receptors expressed on primary macrophages were found to be specific for CGRP. These results suggest that the suppressive effect of AM on the production and gene transcription of TNF-alpha and IL-6 was not mediated by the cAMP signaling pathway. As the alternative signaling pathway, Shimekake et al. (53) have reported that AM increases the intracellular free calcium concentration in the case of bovine aortic endothelial cells. Thus, we deduce that another intracellular signaling pathway than that of cAMP exists in RAW 264.7 cells for AM-induced modulation of cytokine production.

Lipoproteins, such as LDL, ac-LDL, ox-LDL, are found to be factors that stimulate AM production in RAW 264.7 cells. Ox-LDL has been reported to modulate the expression of macrophage colony-stimulating factor mRNA, platelet-derived growth factor-B mRNA, and TNF-alpha mRNA in mouse peritoneal macrophages, and many lines of evidence have demonstrated that these lipoproteins play crucial roles in the development and progression of atherosclerosis (32, 54, 55). Activated macrophages ingest plasma lipoproteins and are then converted into foam cells being stuffed with cholesteryl ester. The resulting foam cells are known to participate in the formation of atherosclerotic plaque. Kohno and co-workers (56) have shown that AM inhibits proliferation of VSMCs with the synthetic phenotype that are also major components of atherosclerotic plaque. In this study, AM production in RAW 264.7 cells is shown to be stimulated with lipoproteins. Based on these data, AM is deduced to participate in the development and progression of atherosclerosis as an inhibitory factor.

In conclusion, this study demonstrate that the macrophage cell line and primary macrophage produce and secrete AM. AM production is dynamically regulated by LPS, steroids, and lipoproteins, as well as RA, TPA, and IFN-gamma which modulate differentiation and activation of macrophages. AM suppresses the secretion and gene transcription of TNF-alpha and IL-6 under stimulation with LPS. These results suggest that AM secreted from macrophages participates in the pathogenesis of sepsis, inflammation, and atherosclerosis.

    ACKNOWLEDGEMENTS

We are grateful to Dr. K. Kitamura and Prof. T. Eto of Miyazaki Medical College for discussion and donation of antiserum against AM and cAMP; Dr. K. Shimokado of this institute for donation of ox-LDL; and M. Nakatani and M. Higuchi of this institute for technical assistance.

    FOOTNOTES

* This work was supported in part by the Special Coordination Fund for the Promotion of Science and Technology from the Science and Technology Agency (Encouragement System of Center of Excellence), by research grants from the Ministry of Health and Welfare, the Ministry of Education, Science and Culture, and the Human Science Foundation of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: National Cardiovascular Center Research Institute, 5-7-1 Fujishirodai, Suita, Osaka 565-8565, Japan. Tel.: 81-6-833-5012 (ext. 2600); Fax: 81-6-872-7485; E-mail: minamino{at}ri.ncvc.go.jp.

1 The abbreviations used are: AM, adrenomedullin; IR, immunoreactive; CGRP, calcitonin gene-related peptide; EC, endothelial cell; VSMC, vascular smooth muscle cell; ELISA, enzyme-linked immunoadsorbent assay; NO, nitric oxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; TPA, 12-O-tetradecanoyl phorbol-13-acetate; RA, retinoic acid; LPS, lipopolysaccharide; IFN-gamma , interferon-gamma ; TNF-alpha , tumor necrosis factor alpha ; IL-1, interleukin-1; IL-6, interleukin-6; TGF-beta , transforming growth factor-beta 1; LDL, low density lipoprotein; ox-LDL, oxidized LDL; ac-LDL, acetylated LDL; DMEM, Dulbecco's modified Eagle's medium; BSA, bovine serum albumin; FCS, fetal calf serum; HPLC, high pressure liquid chromatography; PCR, polymerase chain reaction; RIA, radioimmunoassay; 8-Br-cAMP, 8-bromoadenosine 3',5'-cyclic monophosphate.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Kitamura, K., Kangawa, K., Kawamoto, M., Ichiki, Y., Nakamura, S., Matsuo, H., and Eto, T. (1993) Biochem. Biophys. Res. Commun. 192, 553-560[CrossRef][Medline] [Order article via Infotrieve]
  2. Sakata, J., Shimokubo, T., Kitamura, K., Nakamura, S., Kangawa, K., Matsuo, H., and Eto, T. (1993) Biochem. Biophys. Res. Commun. 195, 921-927[CrossRef][Medline] [Order article via Infotrieve]
  3. Sugo, S., Minamino, N., Kangawa, K., Miyamoto, K., Kitamura, K., Sakata, J., Eto, T., and Matsuo, H. (1994) Biochem. Biophys. Res. Commun. 201, 1160-1166[CrossRef][Medline] [Order article via Infotrieve]
  4. Sugo, S., Minamino, N., Shoji, H., Kangawa, K., Kitamura, K., Eto, T., and Matsuo, H. (1994) Biochem. Biophys. Res. Commun. 203, 719-726[CrossRef][Medline] [Order article via Infotrieve]
  5. Sugo, S., Minamino, N., Shoji, H., Kangawa, K., Kitamura, K., Eto, T., and Matsuo, H. (1994) Biochem. Biophys. Res. Commun. 207, 25-32[CrossRef]
  6. Isumi, Y., Shoji, H., Sugo, S., Tochimoto, T., Yoshioka, M., Kangawa, K., Matsuo, H., and Minamino, N. (1998) Endocrinology 139, 838-846[Abstract/Free Full Text]
  7. Pradines-Figueres, A., and Raetz, C. R. H. (1992) J. Biol. Chem. 267, 23261-23268[Abstract/Free Full Text]
  8. Wang, W. W., Jenkinson, C. P., Griscavage, J. M., Kern, R. M., Arabolos, N. S., Byrns, R. E., Cederbaum, S. D., and Ignarro, L. J. (1995) Biochem. Biophys. Res. Commun. 210, 1009-1016[CrossRef][Medline] [Order article via Infotrieve]
  9. Lambert, L. E., and Paulnock, D. M. (1989) Cell. Immunol. 120, 401-418[Medline] [Order article via Infotrieve]
  10. Shoji, H., Minamino, N., Kangawa, K., and Matsuo, H. (1995) Biochem. Biophys. Res. Commun. 215, 531-537[CrossRef][Medline] [Order article via Infotrieve]
  11. Hirata, Y., Mitaka, C., Sato, K., Nagura, T., Tsunoda, Y., Amaha, K., and Marumo, F. (1996) J. Clin. Endocrinol. & Metab. 81, 1449-1453[Abstract]
  12. Nishio, K., Akai, Y., Murao, Y., Doi, N., Ueda, S., Tabuse, H., Miyamoto, S., Dohi, K., Minamino, N., Shoji, H., Kitamura, K., Kangawa, K., and Matsuo, H. (1997) Crit. Care Med. 25, 953-957[Medline] [Order article via Infotrieve]
  13. Miller, M. J., Martinez, A., Unsworth, E. J., Thiele, C. J., Moody, T. W., Elsasser, T., and Cuttitta, F. (1996) J. Biol. Chem. 271, 23345-23351[Abstract/Free Full Text]
  14. Martinez, A., Miller, M. J., Unsworth, E. J., Siegfried, J. M., and Cuttitta, F. (1995) Endocrinology 136, 4099-4105[Abstract]
  15. Zhao, Y., Hague, S., Manek, S., Zhang, L., Bicknell, R., and Rees, M. C. P. (1998) Oncogene 16, 409-415[CrossRef][Medline] [Order article via Infotrieve]
  16. Raschke, W. C., Baird, S., Ralph, P., and Nakoinz, I. (1978) Cell 15, 261-267[Medline] [Order article via Infotrieve]
  17. Sakata, J., Shimokubo, T., Kitamura, K., Nishizono, M., Iehiki, Y., Kangawa, K., Matsuo, H., and Eto, T. (1994) FEBS Lett. 352, 105-108[CrossRef][Medline] [Order article via Infotrieve]
  18. Caput, D., Beutler, B., Hartog, K., Thayer, R., Brown-Shimer, S. L., and Cerami, A. (1986) Proc. Natl. Acad. Sci. U. S. A. 83, 1670-1674[Abstract]
  19. Grenett, H. E., Fuentes, N. L., and Fuller, G. M. (1990) Nucleic Acids Res. 18, 6455[Medline] [Order article via Infotrieve]
  20. Spengler, R. N., Spengler, M. L., Lincoln, P., Remick, D. G., Strieter, R. M., and Kunkel, S. L. (1989) Infect. Immun. 57, 2837-2841[Medline] [Order article via Infotrieve]
  21. Okazaki, T., Ogawa, Y., Tamura, N., Mori, K., Isse, N., Aoki, T., Rochelle, J. M., Taketo, M. M., Seldin, M. F., and Nakao, K. (1996) Genomics 37, 395-399[CrossRef][Medline] [Order article via Infotrieve]
  22. Sabath, D. E., Broome, H. E., and Prystowsky, M. B. (1990) Gene (Amst.) 91, 185-191[CrossRef][Medline] [Order article via Infotrieve]
  23. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. (1996) Genome Res. 6, 986-994[Abstract]
  24. Gibson, U. E. M., Heid, C. A., and Williams, P. M. (1996) Genome Res. 6, 995-1001[Abstract]
  25. Kitamura, K., Kangawa, K., Kawamoto, K., Ichiki, Y., Matsuo, H., and Eto, T. (1992) Biochem. Biophys. Res. Commun. 185, 134-141[Medline] [Order article via Infotrieve]
  26. Auwerx, J. (1991) Experientia (Basel) 47, 22-31
  27. Frendscho, M. H., Wynn, T. A., Czuprynski, C. J., and Paulnock, D. (1990) Clin. Exp. Immunol. 82, 404-410[Medline] [Order article via Infotrieve]
  28. Migliorini, P., Corradin, G., and Corradin, S. B. (1991) J. Immunol. Methods 139, 107-114[Medline] [Order article via Infotrieve]
  29. Han, J., Thompson, P., and Beutler, B. (1990) J. Exp. Med. 172, 391-394[Abstract]
  30. Hausmann, E. H., Hao, S. Y., Pace, J., and Parmely, M. J. (1994) Infect. Immun. 62, 3625-3632[Abstract]
  31. Sugo, S., Minamino, N., Shoji, H., Kangawa, K., and Matsuo, H. (1995) FEBS Lett. 369, 311-314[CrossRef][Medline] [Order article via Infotrieve]
  32. Brown, M. S., and Goldstein, J. L. (1983) Annu. Rev. Biochem. 52, 223-261[CrossRef][Medline] [Order article via Infotrieve]
  33. Akeson, A. L., Schroeder, K., Woods, C., Schmidt, C. J., and Jones, W. D. (1991) J. Lipid Res. 32, 1699-1707[Abstract]
  34. Vey, E., Zhang, J. H., and Dayer, J. M. (1992) J. Immunol. 149, 2040-2046[Abstract/Free Full Text]
  35. Lambert, L., and Paulnock, D. M. (1989) Cell. Immunol. 120, 401-418[Medline] [Order article via Infotrieve]
  36. Dillehay, D. L., Walia, A. S., and Lamon, E. W. (1988) J. Leukocyte Biol. 44, 353-360[Abstract]
  37. Diaz-Guerra, M. J. M., Bodelon, O. G., Velasco, M., Whelan, R., Parker, P. J., and Bosca, L. (1996) J. Biol. Chem. 271, 32038-32033
  38. Minamino, N., Shoji, H., Sugo, S., Kangawa, K., and Matsuo, H. (1995) Biochem. Biophys. Res. Commun. 211, 686-693[CrossRef][Medline] [Order article via Infotrieve]
  39. Rinehart, J. J., Wuest, D., and Ackerman, G. A. (1982) J. Immunol. 129, 1436-1440[Abstract/Free Full Text]
  40. Di, R. M., Radmski, M., Caruccio, R., and Moncada, S. (1990) Biochem. Biophys. Res. Commun. 172, 1246-1252[Medline] [Order article via Infotrieve]
  41. Snyder, D. S., and Unanue, E. R. (1982) J. Immunol. 129, 1803-1805[Abstract/Free Full Text]
  42. Zanker, B., Walz, G., Wieder, K. J., and Strom, T. B. (1990) Transplantation 49, 183-185[Medline] [Order article via Infotrieve]
  43. Hayashi, T., Nakai, T., and Miyabo, S. (1991) Am. J. Physiol. 261, C106-C114[Abstract/Free Full Text]
  44. Sato, A., Suzuki, H., Iwata, Y., Nakazato, Y., Kato, H., and Saruta, T. (1992) Hypertension 19, 109-115[Abstract]
  45. Kubo, A., Minamino, N., Isumi, Y., Kangawa, K., Dohi, K., and Matsuo, H. (1998) FEBS Lett. 426, 233-237[CrossRef][Medline] [Order article via Infotrieve]
  46. Ziegler-Heitbrock, H. W. L. (1995) J. Inflamm. 45, 13-26[Medline] [Order article via Infotrieve]
  47. Reddy, S. T., Gilbert, R. S., Xie, W., Luner, S., and Herschman, H. R. (1994) J. Leukocyte Biol. 55, 192-200[Abstract]
  48. Ishimitsu, T., Kojima, M., Kangawa, K., Hino, J., Matsuoka, H., Kitamura, K., Eto, T., and Matsuo, H. (1994) Biochem. Biophys. Res. Commun. 203, 631-639[CrossRef][Medline] [Order article via Infotrieve]
  49. McDowell, M. A., Lucas, D. M., Nicolet, C. M., and Paulnock, D. M. (1995) J. Immunol. 155, 4933-4938[Abstract]
  50. Boyte, W. R., Meal, E. A., and English, B. K. (1996) Shock 6, 218-222[Medline] [Order article via Infotrieve]
  51. Chujor, C. S. N., Klein, L., and Lam, C. (1996) Eur. J. Immunol. 26, 1253-1259[Medline] [Order article via Infotrieve]
  52. Kamoi, H., Kanazawa, H., Hirata, K., Kurihara, N., Yano, Y., and Otani, S. (1995) Biochem. Biophys. Res. Commun. 211, 1031-1035[CrossRef][Medline] [Order article via Infotrieve]
  53. Shimekake, Y., Nagata, K., Ohta, S., Kambayashi, Y., Teraoka, H., Kitamura, K., Eto, T., Kangawa, K., and Matsuo, H. (1995) J. Biol. Chem. 270, 4412-4417[Abstract/Free Full Text]
  54. Steinberg, D., Parthasarathy, S., Carew, T. E., Khoo, J. C., and Witztum, J. L. (1989) N. Engl. J. Med. 320, 915-924[Medline] [Order article via Infotrieve]
  55. Witztum, J. L., and Steinberg, D. (1991) J. Clin. Invest. 88, 1785-1792[Medline] [Order article via Infotrieve]
  56. Kano, H., Kohno, M., Yasunari, K., Yokoyama, K., Horio, T., Ikeda, M., Minami, M., Hanehira, T., Takeda, T., and Yoshikawa, J. (1996) J. Hypertens. 14, 209-213[Medline] [Order article via Infotrieve]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.